Novartis gets approval for first malaria drug for babies and children

Novartis has secured approval in Switzerland for Coartem Baby, a groundbreaking medication designed to treat malaria in babies and young children. Eight African nations, including Burkina Faso and Nigeria, are expected to swiftly approve the treatment, known as Riamet Baby in some regions. This dissolvable, cherry-flavored drug fills a critical treatment gap for infants under 4.